Specialty drugs are a top cost driver and a key priority for employers who want to pay for innovation, not waste. Employers want: transparency about the real cost of drugs, suppliers to remove all waste (including low-value drugs) and formularies to be based on clinical efficacy and safety, not rebates. Employers must work together, leveraging their purchasing power to drive innovation and demand accountability.
At this session, participants will:
- Understand how today’s PBM model can dramatically increase employer costs and what to do about it
- Discover how some employers are driving change, being disruptive and offering alternatives to the traditional PBM model
- Hear how current M&A activity will impact employers